HomeCompareWHCA vs ABBV

WHCA vs ABBV: Dividend Comparison 2026

WHCA yields 800.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WHCA wins by $2773896.36M in total portfolio value
10 years
WHCA
WHCA
● Live price
800.00%
Share price
$0.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2773896.46M
Annual income
$2,226,430,694,490.38
Full WHCA calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — WHCA vs ABBV

📍 WHCA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWHCAABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WHCA + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WHCA pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WHCA
Annual income on $10K today (after 15% tax)
$68,000.00/yr
After 10yr DRIP, annual income (after tax)
$1,892,466,090,316.82/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, WHCA beats the other by $1,892,466,069,260.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WHCA + ABBV for your $10,000?

WHCA: 50%ABBV: 50%
100% ABBV50/50100% WHCA
Portfolio after 10yr
$1386948.28M
Annual income
$1,113,215,359,631.07/yr
Blended yield
80.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

WHCA
No analyst data
Altman Z
2286.2
Piotroski
0/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WHCA buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWHCAABBV
Forward yield800.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$2773896.46M$102.3K
Annual income after 10y$2,226,430,694,490.38$24,771.77
Total dividends collected$2730603.49M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: WHCA vs ABBV ($10,000, DRIP)

YearWHCA PortfolioWHCA Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$90,700$80,000.00$11,550$430.00+$79.2KWHCA
2$775,180$678,130.84$13,472$627.96+$761.7KWHCA
3$6,246,019$5,416,576.76$15,906$926.08+$6.23MWHCA
4$47,472,138$40,788,897.61$19,071$1,382.55+$47.45MWHCA
5$340,525,323$289,730,135.14$23,302$2,095.81+$340.50MWHCA
6$2,306,680,888$1,942,318,792.24$29,150$3,237.93+$2306.65MWHCA
7$14,764,459,529$12,296,310,979.28$37,536$5,121.41+$14764.42MWHCA
8$89,354,478,583$73,556,506,887.09$50,079$8,338.38+$89354.43MWHCA
9$511,650,252,638$416,040,960,553.41$69,753$14,065.80+$511650.18MWHCA
10$2,773,896,464,813$2,226,430,694,490.38$102,337$24,771.77+$2773896.36MWHCA

WHCA vs ABBV: Complete Analysis 2026

WHCAStock

Williston Holding Company, Inc. owns and operates restaurants. The company was incorporated in 2012 and is based in Eden Prairie, Minnesota.

Full WHCA Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this WHCA vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WHCA vs SCHDWHCA vs JEPIWHCA vs OWHCA vs KOWHCA vs MAINWHCA vs JNJWHCA vs MRKWHCA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.